Skip to main content

Table 1 Demographic and laboratory findings in the control and CLL groups

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

VariablesEntire population N = 83CLL group N = 42Control group N = 41p
Age (years)62.8 ± 10.063.9 ± 9.861.7 ± 10.20.326
Gender
 Female39 (47.0)14 (33.3)25 (61.0)0.016*
 Male44 (53.0)28 (66.7)16 (39.0)
Haemoglobin (g/dL)12.6 ± 2.112.5 ± 2.212.7 ± 2.00.707
WBCs (×103/μL)13.7 (2.6–131)27.1 (5.8–131)7.7 (2.6–16.3)< 0.001*
Neutrophils (×103/μL)4.7 (0.6–11.7)5.5 (0.6–11.5)4.6 (1.9–11.7)0.078
Lymphocytes (×103/μL)5 (0.4–123)21.3 (5–123)2.1 (0.4–4.1)< 0.001*
Platelets (×103/μL)225 (24–630)200 (24–463)253 (49–630)0.008*
ELABELA (ng/ml)4.6 (0.1–19.7)6.7 (0.6–19.7)2 (0.1–8.6)< 0.001*
  1. Numerical variables are presented as mean ± standard deviation or median (min-max) according to normality distribution. Categorical variables are presented as number (%)
  2. * P < 0.05 indicates statistical significance
  3. Abbreviations: CLL Chronic lymphocytic leukaemia, WBC White blood cell